Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13014842 | 0.88 | CYP3A4 (0.64) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL8520522 | 0.88 | CYP3A4 (0.64) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL204226 | 0.86 | CYP3A4 (0.72) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL2708818 | 0.86 | CYP3A4 (0.72) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL20707007 | 0.84 | CYP3A4 (0.75) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL3265918 | 0.84 | CYP3A4 (0.75) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL5993163 | 0.84 | CYP3A4 (0.75) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL1914011 | 0.83 | CYP3A4 (0.74) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL15260813 | 0.83 | CYP3A4 (0.74) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL8520521 | 0.83 | CYP3A4 (0.74) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394279-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2368890-B9 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-10-30 | — | — | EP | disclosed |
| EP-2628481-A1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | AbbVie Bahamas Ltd. (BS) | 2013-08-21 | — | — | EP | disclosed |
| EP-2368890-B1 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-04-17 | — | — | EP | disclosed |
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885NR1I2 2411/4885 |
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885NR1I2 2411/4885 |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885NR1I2 2411/4885 |
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885NR1I2 2411/4885 |
| US-20150218194-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885NR1I2 2411/4885 |
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP3A4 1792/4885CYP2C9 3780/4885NR1I2 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.